Akkermansia muciniphila AK32 Strain for Improving Intestinal Function
Summary
The USPTO granted patent US12605414B2 to The Asan Foundation for an Akkermansia muciniphila AK32 strain (Accession No. KCTC 14172BP) and its use for preventing or improving intestinal damage. The patent covers the bacterial strain itself as well as a method for administering an effective amount of the strain or its culture as an active ingredient to treat intestinal damage. Three claims are included in the granted patent.
What changed
The USPTO issued patent US12605414B2 granting The Asan Foundation exclusive rights to the Akkermansia muciniphila AK32 strain (KCTC 14172BP) and its therapeutic applications for intestinal damage. The patent includes claims covering the bacterial strain composition and a method of treatment involving administering an effective amount of the strain or its culture. The filing date was May 7, 2021, and the application number is 17998537.
For entities in the probiotic, pharmaceutical, or functional food sectors, this granted patent establishes intellectual property barriers around Akkermansia muciniphila-based products for intestinal health applications. Companies developing similar probiotic strains or therapeutic formulations targeting intestinal damage should conduct freedom-to-operate analyses to assess potential infringement risks associated with this patent family.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Discovery of novel Akkermansia muciniphila AK32 and application thereof for improving intestinal function
Grant US12605414B2 Kind: B2 Apr 21, 2026
Assignee
THE ASAN FOUNDATION
Inventors
Mi-Na Kweon, Seungil Kim
Abstract
An Akkermansia muciniphila AK32 (Accession No. KCTC 14172BP) strain. The Akkermansia muciniphila AK32 strain prevents or improves intestinal damage. A method for preventing, improving or treating intestinal damage, including administering to a subject an effective amount of the Akkermansia muciniphila AK32 strain or a culture thereof as an active ingredient.
CPC Classifications
A61K 35/741 A61K 35/74 A61P 1/04 A61P 1/00 C12N 1/205 C12N 1/20 C12R 2001/01 A23L 33/135
Filing Date
2021-05-07
Application No.
17998537
Claims
3
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.